TITLE

Inimex Nets $22M in Series B to Advance Innate Defense Drugs

AUTHOR(S)
Turner, Tiffany
PUB. DATE
June 2008
SOURCE
BioWorld Today;6/3/2008, Vol. 19 Issue 107, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article talks about the successful Series B financing held by Inimex Pharmaceuticals Inc., that it expects to bring it closer to conducting clinical trials of its Innate Defense Regulator drugs. The company raised $22 million to grow its portfolio, which includes a number of potential products aimed at combating antibiotic resistance and inflammation. The three new investors attracted by the company are Morningside Venture Investments Ltd., Roche Venture Fund and Astellas Venture Management LLC.
ACCESSION #
32481738

 

Related Articles

  • Financial Steps for Sites. Warnock, Neil; Lester, Matthew // Applied Clinical Trials;2010 Partnerships Supplement, p20 

    The article explains that the key to clinical trial management is dependent to the management of financial data. It notes that successful financial results demand sites to select studies that maximize strategic and financial goals and effectively manage budgets, collection and patient accrual....

  • INIMEX RAISES US $22 MIL AGAINST ANTIBIOTIC RESISTANCE.  // Biotech Financial Reports;Jul2008, Vol. 15 Issue 7, p1 

    The article reports on the $22 million venture funds received by Inimex Pharmaceuticals, Inc. The venture funds allow Inimex Pharmaceuticals, Inc. to conduct clinical trials of an Innate defense Regulator (IDR) drug in patients. They are donated by several investors including Morningside Venture...

  • Inimex Nets $22M to Advance Innate Defense.  // Bioworld Week;6/9/2008, Vol. 16 Issue 23, p2 

    The article reports that Inimex Pharmaceuticals Inc. of Vancouver, British Columbia has raised $22 million to advance its portfolio which includes products for combating antibiotic resistance and inflammation. The company is developing a series of non-antibiotic drugs designed to trigger the...

  • Cerenis' Series C Adds €40M for HDL Mimetic in CV Disease. Boggs, Jennifer // BioWorld Today;7/27/2010, Vol. 21 Issue 143, p1 

    The article offers information on the third financing round by Cerenis Therapeutics SA. The Series C funding amounted to 40 million euros and will be used for the advancement of its HDL-mimetic CER-001 into a Phase II trial in patients with cardiovascular disease. The deal, led by Fund for...

  • Avexa Raises $60.1M To Fund Phase III Trials Of HIV Agent. Shrine, Jim // BioWorld Today;3/22/2007, Vol. 18 Issue 56, p1 

    The article reports on the total amount of funds raised by Avexa Ltd. to finance the Phase III trials of its lead HIV compound. The total amount of the funds is Australian $75 million. The breakdown of the funds include an Australian $15 million private placement with U.S. investors and...

  • Sunesis' $28.5M Stock Sale to Fund Voreloxin Phase III Trial. Hollingsworth, Catherine // BioWorld Today;7/2/2010, Vol. 21 Issue 127, p3 

    The article reports on the 28.5 million U.S. dollar stock sale closed by Sunesis Pharmaceuticals Inc. in the final part its 2009 private placement of stock. According to the company, the funds generated from the sale will be allocated to a pivotal Phase III trial of voreloxin in patients with...

  • Serentis Raises $20.8M In First VC Funding Round. Moran, Nuala // BioWorld International;7/4/2007, Vol. 12 Issue 27, p2 

    The article reports that pharmaceutical firm Serentis Ltd. has raised $20.8 million in venture funds for its on-going trials for its drugs. The company is developing a drug for treating chemotherapy-induced mucositisma and a wound care treatment with analgesic properties. Some of the projects'...

  • CoLucid Raises $25M in Series B to Fund Migraine Drug Work. Hollingsworth, Catherine // BioWorld Today;7/2/2008, Vol. 19 Issue 128, p1 

    The article reports that CoLucid Pharmaceuticals Inc. has completed a $25 million Series B financing in July 2008 to fund further clinical testing of its lead compound, COL-144, for treating migraine. Completion for its Phase II testing as an intravenous treatment has been completed and is in...

  • INTERMUNE INC.  // MondayMorning;1/21/2013, Vol. 21 Issue 2, p1 

    The article informs that InterMune Inc. is planning to sell its 85 million U.S. dollars in debt and 12.5 million shares of stock in a public offering. The company aims to use the offering to fund its late-stage clinical trial and sales of its drug Esbriet for chronic obstructive pulmonary...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics